Cargando…

1262. Dolutegravir Plus 3TC In Antiretroviral Experienced Adults: Immunovirological Outcomes In a Multicenter Retrospective Cohort In Spain

BACKGROUND: Dolutegravir-based dual therapies for treating people living with HIV (PLHIV) are strategies strongly recommended in several practice guidelines. The safety and efficacy combination of Dolutegravir (DTG) plus 3TC as a switching strategy in virologically suppressed patients was demonstrat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Buzón-Martín, Luis, Dueñas Gutierrez, Carlos, Iribarren, José Antonio, de los Santos, Ignacio, Santiago, Alberto Diaz-De, Morán-Rodríguez, Miguel Ángel, Pousada, Guillermo, Rico, Claudia González, García, Estela Moreno, Ferreira, Eva, Gómez, Alicia Iglesias, gómez, Cristina Martín, Barquero, Julia gómez, Egido Murciano, Miguel V, Troya, Jesús
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752996/ http://dx.doi.org/10.1093/ofid/ofac492.1093

Ejemplares similares

Dolutegravir Plus 3TC in Virologically Suppressed PLWHIV: Immunological Outcomes in a Multicenter Retrospective Cohort in Spain during the COVID-19 Pandemic
por: Buzón, Luis, et al.
Publicado: (2023)

Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV
por: Dueñas-Gutiérrez, Carlos, et al.
Publicado: (2023)

Predict the Effects of Dolutegravir (DTG) Plus Lamivudine (3TC) on Immunological Responses in People Living with HIV (PLWHIV)
por: Troya, Jesús, et al.
Publicado: (2023)

Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study
por: Troya, Jesús, et al.
Publicado: (2022)

Editorial: Computational systems immunovirology
por: Zarei Ghobadi, Mohadeseh, et al.
Publicado: (2023)

1598. Predictive equations for immune recovery at 48 weeks of BIC/FTC/TAF treatment in Virologically Suppressed PLWHIV.
por: Tomé, Roberto Pedrero, et al.
Publicado: (2023)

Introducing the Immunovirology Section of Journal of Translational Medicine
por: Buonaguro, Luigi
Publicado: (2010)

Facial Trauma: A Retrospective Study of 1262 Patients
por: Bocchialini, Gabriele, et al.
Publicado: (2019)

Virological ultrastructural investigation in 1262 cases of children gastroenteritis
por: Falcieri, E., et al.
Publicado: (1983)

Construction of Antibody Phage Libraries and Their Application in Veterinary Immunovirology
por: Bashir, Shahbaz, et al.
Publicado: (2020)

HIV-1 elite controllers: an immunovirological review and clinical perspectives
por: Gebara, Nour Y, et al.
Publicado: (2019)

1262. Comparative Evaluation of Native and Migrant HIV+ Pregnant Women in Chile
por: silva, macarena, et al.
Publicado: (2019)

Impact of variability in adherence to HIV antiretroviral therapy on the immunovirological response and mortality
por: Boussari, Olayidé, et al.
Publicado: (2015)

The Importance of Mouse Models to Define Immunovirologic Determinants of Progressive Multifocal Leukoencephalopathy
por: Frost, Elizabeth L., et al.
Publicado: (2015)

P1262: EZH2 INHIBITORS MEDIATE PLATINUM RESISTANCE BY ENHANCED EFFLUX
por: Groß, E., et al.
Publicado: (2022)

Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Naive and Treatment-Experienced Patients in Canada
por: Despiégel, Nicolas, et al.
Publicado: (2015)

48-Week effectiveness and tolerability of dolutegravir (DTG) + lamivudine (3TC) in antiretroviral-naïve adults living with HIV: A multicenter real-life cohort
por: Cabello-Ubeda, Alfonso, et al.
Publicado: (2022)

Immunovirological markers in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP)
por: Enose-Akahata, Yoshimi, et al.
Publicado: (2019)

miR-1262 suppresses gastric cardia adenocarcinoma via targeting oncogene ULK1
por: Zheng, Yan, et al.
Publicado: (2021)

Dolutegravir is not associated with weight gain in antiretroviral therapy experienced geriatric patients living with HIV
por: Guaraldi, Giovanni, et al.
Publicado: (2021)

NF-κB downstream miR-1262 disturbs colon cancer cell malignant behaviors by targeting FGFR1: NF-κB/miR-1262/FGFR1 modulates colon cancer oncogenesis
por: Zhang, Weilin, et al.
Publicado: (2023)

Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Experienced (TE) Patients in France
por: Pialoux, Gilles, et al.
Publicado: (2015)

Emergent dolutegravir resistance in integrase-naïve, treatment experienced patients from Zimbabwe
por: Mandikiyana Chirimuta, Linda A., et al.
Publicado: (2022)

Escalating and sustained immunovirological dissociation among antiretroviral drug-experienced perinatally human immunodeficiency virus-1-infected children and adolescents living in the Central African Republic: A STROBE-compliant study
por: Mossoro-Kpinde, Christian Diamant, et al.
Publicado: (2020)

Immunovirological discordance among female sex workers who start antiretroviral therapy in Burkina Faso
por: Bazié, Wilfried Wenceslas, et al.
Publicado: (2022)

Safety and Efficacy of Dolutegravir Plus Rilpivirine in Treatment-Experienced HIV-Infected Patients: The DORIVIR Study
por: Palacios, Rosario, et al.
Publicado: (2018)

Switch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational Cohort
por: Capetti, Amedeo F., et al.
Publicado: (2016)

1262. Investigation and Mitigation of a Multi-Species Outbreak of Invasive Fungal Infections on Two Oncology Wards
por: Huslage, Kirk, et al.
Publicado: (2018)

1262. The Impact of Antimicrobial Stewardship on Antimicrobial Consumption and Resistance Trends at a Tertiary Care Center in Beirut
por: Haddad, Nisrine, et al.
Publicado: (2023)

Outcome in hip fracture patients related to anemia at admission and allogeneic blood transfusion: an analysis of 1262 surgically treated patients
por: Vochteloo, Anne JH, et al.
Publicado: (2011)

2486. Clinical Outcomes of Patients Treated with Dolutegravir Functional Monotherapy or Dolutegravir plus an Active Non-cytosine Nucleoside Analog: A Retrospective Observational Cohort Study of Treatment-Experienced Patients
por: Rolle, Charlotte-Paige M, et al.
Publicado: (2019)

The Judicialization of Health and the Quest for State Accountability: Evidence from 1,262 Lawsuits for Access to Medicines in Southern Brazil
por: Biehl, João, et al.
Publicado: (2016)

1262. Antimicrobial Activity of Gepotidacin against Clinical Isolates of Escherichia coli and Staphylococcus saprophyticus Collected Worldwide in 2019
por: Arends, S J Ryan, et al.
Publicado: (2020)

1571. BIC/FTC/TAF in Virologically Suppressed PLWHIV: 48-96 weeks RETROBIC Multicenter Cohort study results.
por: Estévez, Samuel, et al.
Publicado: (2023)

Rildo: Real-World Multicenter Study on the Effectiveness and Safety of Single-Tablet Regimen of Dolutegravir plus Rilpivirine in Treatment-Experienced People Living with HIV
por: Hidalgo-Tenorio, Carmen, et al.
Publicado: (2022)

Use of dolutegravir in two INI-experienced patients with multiclass resistance resulted in excellent virological and immunological responses
por: Marije Hofstra, Laura, et al.
Publicado: (2014)

Safety and efficacy of elvitegravir, dolutegravir, and raltegravir in a real-world cohort of treatment-naïve and -experienced patients
por: Brehm, Thomas Theo, et al.
Publicado: (2019)

Immunovirological and environmental screening reveals actionable risk factors for fatal COVID-19 during post-vaccination nursing home outbreaks
por: Cuypers, Lize, et al.
Publicado: (2023)

Immunovirological response to combined antiretroviral therapy and drug resistance patterns in children: 1- and 2-year outcomes in rural Uganda
por: Ahoua, Laurence, et al.
Publicado: (2011)

Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as an early predictor of COVID-19 mortality
por: Brunet-Ratnasingham, Elsa, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6hfn1v34r1jfk92g78vs77ulje